Inflection Biosciences Announces Pre-clinical Data on IBL-202 to be Presented at IWCLL 2017

(15 May 2017)

Dublin, Ireland, May 15th, 2017 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that that new data on IBL-202, a dual mechanism PIM/PI3 kinase inhibitor, will be highlighted in a poster at the XVII International Workshop on Chronic Lymphocytic Leukaemia 2017, to be held May 12-15, 2017 in New York City.

The pre-clinical data was generated through a collaboration with Dr. Oliver Giles Best of the Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Australia, and a member of the CLL Australian Research Consortium (CLLARC), Sydney, Australia.

The poster entitled, “The dual PIM/PI3-kinase inhibitor IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment” will be presented by Dr. Kyle Crassini at 6.00 pm on Tuesday, May 16th, 2017.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signalling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

Image

Search

Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2017 Inflection Biosciences.   Web Design by Webtrade